UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January 2026
Commission file number: 001-42834
REGENTIS BIOMATERIALS LTD.
(Translation of registrant’s name into English)
60 Medinat Hayehudim Street, 4676652, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
CONTENTS
Attached hereto and incorporated
herein is the registrant’s press release issued on January 6, 2026, titled “Regentis’ GelrinC Establishes Long-Term
Durability of Cartilage Repair Through Quantitative MOCART Evaluation.”
A copy of the press release
is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release titled: “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation” |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Regentis Biomaterials Ltd. |
| |
|
| Date: January 6, 2026 |
By: |
/s/ Ehud Geller |
| |
Name: |
Ehud Geller |
| |
Title: |
Chairman and Chief Executive Officer |
